Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
leuprorelin (CKD-841) / Chong Kun Dang
NCT04840745: The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1	Not yet recruiting	1	32	RoW	CKD-841 A-1 3.75mg, CKD-841, CKD-841 A-1 1.88mg, CKD-841 D 2.92mg, Leuplin Inj. 3.75 mg, Leuplin.Inj	Chong Kun Dang Pharmaceutical, Severance Hospital	Early Puberty	10/21	11/21